secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Healthcare Acquisition Corp. (—)
CIK:        0001839185
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001104659-23-033374
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Healthcare completes de-SPAC merger with YS Biopharma; shares begin trading March 17
--------------------------------------------------------------------------------

- Business combination closed March 16, 2023; YS Biopharma Ordinary Shares and Warrants to trade under YS and YSBPW.
- 19,388,769 Summit Class A shares redeemed at ~$10.10/share, totaling ~$195.8M in redemptions.
- SPAC Class A exchange ratio of 1.4286; up to 1,708,497 YS Biopharma shares issued to non-redeeming holders.
- All Summit directors and officers resigned; Yi Zhang (YS Biopharma chairman) becomes sole director of surviving entity.
- Summit's securities delisted from Nasdaq; Form 25 filed; deregistration to follow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1839185/000110465923033374/0001104659-23-033374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1839185/000110465923033374/tm239524d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-033374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer